Monarch Partners Asset Management’s Charles River Laboratories CRL Stock Holding History

Monarch Partners Asset Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$397K	Buy	+1,820	New	+$397K	0.12%	133
2022 Q3	–	Sell	-3,655	Closed	-$782K	–	143
2022 Q2	$782K	Buy	3,655 +1,375	+60%	+$336K	0.22%	138
2022 Q1	$647K	Buy	+2,280	New	+$703K	0.14%	145
2020 Q4	–	Sell	-1,875	Closed	-$425K	–	182
2020 Q3	$425K	Buy	1,875 +471	+34%	+$97.7K	0.1%	151
2020 Q2	$245K	Sell	1,404 -27,013	-95%	-$4.31M	0.06%	171
2020 Q1	$3.59M	Buy	28,417 +25,656	+929%	+$3.85M	1.26%	33
2019 Q4	$422K	Sell	2,761 -44,984	-94%	-$6.23M	0.09%	156
2019 Q3	$6.32M	Buy	+47,745	New	+$6.4M	0.95%	46
2019 Q2	–	Sell	-45,160	Closed	-$6.56M	–	172
2019 Q1	$6.56M	Sell	45,160 -9,332	-17%	-$1.23M	0.99%	43
2018 Q4	$6.17M	Sell	54,492 -53,933	-50%	-$6.75M	0.89%	45
2018 Q3	$14.6M	Buy	+108,425	New	+$13.4M	1.32%	20
2018 Q1	–	Sell	-34,973	Closed	-$3.83M	–	198
2017 Q4	$3.83M	Sell	34,973 -19,070	-35%	-$2.08M	0.36%	99
2017 Q3	$5.84M	Sell	54,043 -26,660	-33%	-$2.74M	0.56%	75
2017 Q2	$8.16M	Sell	80,703 -45,000	-36%	-$4.14M	0.81%	47
2017 Q1	$11.3M	Sell	125,703 -105,607	-46%	-$8.97M	1.13%	32
2016 Q4	$17.6M	Buy	231,310 +105,764	+84%	+$8.03M	1.5%	18
2016 Q3	$10.5M	Buy	125,546 +4,676	+4%	+$392K	0.98%	42
2016 Q2	$9.96M	Sell	120,870 -103,430	-46%	-$8.52M	1%	38
2016 Q1	$17M	Buy	224,300 +137,500	+158%	+$10.2M	1.76%	8
2015 Q4	$6.98M	Buy	+86,800	New	+$6.26M	0.73%	58
2015 Q2	–	Sell	-30,325	Closed	-$2.4M	–	179
2015 Q1	$2.4M	Sell	30,325 -81,464	-73%	-$6.01M	0.48%	87
2014 Q4	$7.11M	Sell	111,789 -50,321	-31%	-$3.15M	1.55%	15
2014 Q3	$9.68M	Buy	162,110 +47,600	+42%	+$2.72M	2.55%	1
2014 Q2	$6.13M	Buy	114,510 +8,490	+8%	+$466K	1.61%	10
2014 Q1	$6.4M	Buy	106,020 +80,518	+316%	+$4.69M	2.33%	2
2013 Q4	$1.35M	Buy	+25,502	New	+$1.28M	0.5%	84

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Monarch Partners Asset Management's CRL Position: Q4 2022 in Review

Monarch Partners Asset Management opened a new position in Charles River Laboratories (CRL) in Q4 2022: 1,820 shares worth $397K. The stake represents 0.12% of the portfolio and ranks #133 among its holdings. This is a return to the name: Monarch Partners Asset Management previously reported a position in CRL as recently as Q2 2022.

Monarch Partners Asset Management first reported a position in CRL in Q4 2013 and has held it in 26 quarters since. The position peaked at $17.6M in Q4 2016. 627 funds tracked by Wall St. Rank hold CRL as of Q4 2022.

Monarch Partners Asset Management held 1,820 shares of Charles River Laboratories worth $397K as of Q4 2022.
Charles River Laboratories was a new Monarch Partners Asset Management position in Q4 2022.
Charles River Laboratories made up 0.12% of Monarch Partners Asset Management's portfolio in Q4 2022, its #133 holding.
Monarch Partners Asset Management first reported a position in Charles River Laboratories in Q4 2013 and has held it in 26 quarters since.
Monarch Partners Asset Management's Charles River Laboratories position peaked at $17.6M in Q4 2016.
627 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2022.

Based on Monarch Partners Asset Management's 13F filing for Q4 2022, filed 2 Feb 2023.